MedTrace Logo

Assessment of 14-3-3 η (Eta) Protein Antibodies in the Serum of Rheumatoid Arthritis Patients and Its Relation to Atherosclerosis.

NCT04937140 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2021-06-23

No results posted yet for this study

Summary

The aims of this study are: • To assess 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and its relation to disease activity and severity. • To investigate the role of 14-3-3 η (eta) protein in the diagnosis or assessment of subclinical carotid artery atherosclerosis.

Conditions

Interventions

DIAGNOSTIC_TEST

14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients

assessment of 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • doaa adel, specialist · In the Medical Administration Sohag University

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2022-08-31
Completion
2022-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04937140 on ClinicalTrials.gov